Aankondiging • May 02
Biofrontera AG, Annual General Meeting, Jun 10, 2026 Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 20
Full year 2025 earnings released: €0.62 loss per share (vs €0.72 loss in FY 2024) Full year 2025 results: €0.62 loss per share. Revenue: €13.2m (down 39% from FY 2024). Net loss: €6.81m (loss widened 57% from FY 2024). New Risk • Dec 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (€16.2m market cap, or US$19.1m). Aankondiging • Oct 24
Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG. Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities.
Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026. New Risk • Jul 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (€14.3m market cap, or US$16.8m). Reported Earnings • Jun 03
First quarter 2025 earnings released: EPS: €0.11 (vs €0.84 loss in 1Q 2024) First quarter 2025 results: EPS: €0.11 (up from €0.84 loss in 1Q 2024). Revenue: €5.77m (up 55% from 1Q 2024). Net income: €678.0k (up €3.39m from 1Q 2024). Profit margin: 12% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Aankondiging • Apr 18
Biofrontera AG, Annual General Meeting, May 28, 2025 Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 17
Full year 2024 earnings released: €0.72 loss per share (vs €0.12 loss in FY 2023) Full year 2024 results: €0.72 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €21.7m (down 33% from FY 2023). Net loss: €4.35m (loss widened €3.98m from FY 2023). Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Over the last 3 years on average, earnings per share has fallen by 55% per year whereas the company’s share price has fallen by 52% per year. Reported Earnings • Dec 01
Third quarter 2024 earnings released: €0.15 loss per share (vs €1.05 loss in 3Q 2023) Third quarter 2024 results: €0.15 loss per share (improved from €1.05 loss in 3Q 2023). Revenue: €3.52m (down 50% from 3Q 2023). Net loss: €931.0k (loss narrowed 70% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 6 percentage points per year, which is a significant difference in performance. Aankondiging • Nov 24
Biofrontera AG announced that it has received $4.2 million in funding Biofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes. New Risk • Oct 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.0m free cash flow). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.4m market cap, or US$16.0m). Reported Earnings • Oct 02
Second quarter 2024 earnings released: €0.023 loss per share (vs €0.12 profit in 2Q 2023) Second quarter 2024 results: €0.023 loss per share (down from €0.12 profit in 2Q 2023). Revenue: €3.49m (down 71% from 2Q 2023). Net loss: €2.64m (down €2.97m from profit in 2Q 2023). Aankondiging • Sep 26
Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024 Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024 Aankondiging • Jul 23
Biofrontera AG, Annual General Meeting, Aug 28, 2024 Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time. New Risk • Jun 19
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€16.7m market cap, or US$18.0m). Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €2.47, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 96% over the past three years. Reported Earnings • Jun 04
First quarter 2024 earnings released: €0.04 loss per share (vs €1.05 loss in 1Q 2023) First quarter 2024 results: €0.04 loss per share (improved from €1.05 loss in 1Q 2023). Revenue: €3.71m (down 36% from 1Q 2023). Net loss: €2.71m (loss narrowed 22% from 1Q 2023). Aankondiging • May 16
Biofrontera AG to Report Q1, 2024 Results on May 31, 2024 Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024 Reported Earnings • May 01
Full year 2023 earnings released: €0.01 loss per share (vs €0.77 loss in FY 2022) Full year 2023 results: €0.01 loss per share (improved from €0.77 loss in FY 2022). Revenue: €32.2m (up 25% from FY 2022). Net loss: €369.0k (loss narrowed 99% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Aankondiging • Apr 24
Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024 Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024 Aankondiging • Nov 07
Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023 Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023 Aankondiging • Jul 14
Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023 Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023 Aankondiging • Jul 06
Biofrontera Launches Novel Belixos Active Care Biofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences. Aankondiging • May 30
Biofrontera AG to Report Q1, 2023 Results on May 31, 2023 Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023 Aankondiging • May 18
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial Biofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023. Aankondiging • May 13
Biofrontera AG, Annual General Meeting, Jun 20, 2023 Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen Germany Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 3 analysts covering Biofrontera expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.60m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Price Target Changed • Nov 25
Price target decreased to €5.50 Down from €6.80, the current price target is an average from 3 analysts. New target price is 206% above last closing price of €1.80. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.21 next year compared to a net loss per share of €0.24 last year. Major Estimate Revision • Nov 25
Consensus EPS estimates fall to -€0.21 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €30.4m to €28.7m. Losses expected to increase from -€0.14 to -€0.21. Biotechs industry in Germany expected to see average net income growth of 4.0% next year. Consensus price target down from €6.80 to €5.50. Share price fell 4.0% to €1.80 over the past week. Breakeven Date Change • Nov 25
No longer forecast to breakeven The 3 analysts covering Biofrontera no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.50m in 2023. New consensus forecast suggests the company will make a loss of €1.50m in 2023. Reported Earnings • Nov 19
Third quarter 2021 earnings released: €0.095 loss per share (vs €0.13 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €5.38m (up 14% from 3Q 2020). Net loss: €5.39m (loss narrowed 17% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 20
Second quarter 2021 earnings released: €0.07 loss per share (vs €0.001 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: €7.62m (down 21% from 2Q 2020). Net loss: €4.00m (loss widened €3.92m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jun 18
Price target increased to €6.80 Up from €5.40, the current price target is an average from 3 analysts. New target price is 134% above last closing price of €2.91. Stock is down 7.8% over the past year. Major Estimate Revision • May 20
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€0.38 to -€0.31 per share. Revenue forecast unchanged from €29.4m at last update. Biotechs industry in Germany expected to see average net income growth of 2.4% next year. Consensus price target of €6.90 unchanged from last update. Share price rose 14% to €2.69 over the past week. Reported Earnings • May 12
First quarter 2021 earnings released: €0.09 loss per share (vs €0.14 loss in 1Q 2020) The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: €5.48m (down 15% from 1Q 2020). Net loss: €4.88m (loss narrowed 11% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Price Target Changed • May 11
Price target decreased to €6.90 Down from €10.33, the current price target is an average from 3 analysts. New target price is 190% above last closing price of €2.38. Stock is down 18% over the past year. Reported Earnings • Apr 14
Full year 2020 earnings released: €0.24 loss per share (vs €0.17 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €30.3m (down 2.9% from FY 2019). Net loss: €13.0m (loss widened 77% from FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 10
Price target raised to €10.33 Up from €8.07, the current price target is an average from 3 analysts. The new target price is 303% above the current share price of €2.57. As of last close, the stock is down 38% over the past year. Executive Departure • Mar 02
CFO & Member of the Executive Board has left the company On the 28th of February, Thomas Schaffer's tenure as CFO & Member of the Executive Board ended after 7.8 years in the role. As of December 2020, Thomas personally held 22.02k shares (€67k worth at the time). Thomas is the only executive to leave the company over the last 12 months. Is New 90 Day High Low • Feb 23
New 90-day low: €2.82 The company is down 10.0% from its price of €3.12 on 25 November 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.81 per share. Price Target Changed • Jan 30
Price target raised to €8.55 Up from €7.93, the current price target is an average from 3 analysts. The new target price is 163% above the current share price of €3.25. As of last close, the stock is down 37% over the past year. Is New 90 Day High Low • Jan 11
New 90-day high: €3.37 The company is up 3.0% from its price of €3.28 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.94 per share. Is New 90 Day High Low • Dec 12
New 90-day low: €2.83 The company is down 24% from its price of €3.74 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.69 per share. Reported Earnings • Nov 13
Third quarter 2020 earnings released: €0.11 loss per share The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: €4.71m (down 8.6% from 3Q 2019). Net loss: €6.46m (loss narrowed 44% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 03
New 90-day low: €2.87 The company is down 33% from its price of €4.31 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €35.72 per share.